Zoetis Inc. $ZTS Shares Bought by Cohen Capital Management Inc.

Cohen Capital Management Inc. lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 91.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 32,055 shares of the company’s stock after acquiring an additional 15,306 shares during the quarter. Cohen Capital Management Inc.’s holdings in Zoetis were worth $4,033,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. Sierra Legacy Group acquired a new stake in shares of Zoetis during the fourth quarter worth approximately $951,000. Savvy Advisors Inc. raised its holdings in Zoetis by 35.5% in the fourth quarter. Savvy Advisors Inc. now owns 3,794 shares of the company’s stock valued at $477,000 after acquiring an additional 993 shares in the last quarter. Hanson & Doremus Investment Management raised its holdings in Zoetis by 17.7% in the fourth quarter. Hanson & Doremus Investment Management now owns 1,939 shares of the company’s stock valued at $244,000 after acquiring an additional 291 shares in the last quarter. Sheets Smith Wealth Management boosted its stake in Zoetis by 42.3% during the 4th quarter. Sheets Smith Wealth Management now owns 2,436 shares of the company’s stock valued at $306,000 after acquiring an additional 724 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. grew its holdings in Zoetis by 113.9% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,767 shares of the company’s stock worth $222,000 after acquiring an additional 941 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS opened at $117.83 on Friday. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The company’s 50-day moving average price is $122.71 and its 200 day moving average price is $128.09. Zoetis Inc. has a fifty-two week low of $113.29 and a fifty-two week high of $172.23. The firm has a market cap of $49.74 billion, a price-to-earnings ratio of 19.57, a price-to-earnings-growth ratio of 1.80 and a beta of 0.98.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The company had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.Zoetis’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. Zoetis’s payout ratio is currently 35.22%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ZTS. Morgan Stanley set a $160.00 target price on shares of Zoetis in a research report on Thursday, December 18th. UBS Group set a $136.00 price objective on Zoetis in a report on Thursday, January 29th. Barclays initiated coverage on Zoetis in a research note on Monday, December 8th. They set an “equal weight” rating and a $136.00 price objective on the stock. HSBC set a $140.00 target price on Zoetis in a report on Wednesday, December 10th. Finally, Bank of America boosted their price target on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Friday, February 13th. Six investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.